Hongli Chen

Hongli Chen


Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 April 2025 in Alzheimer's Research & Therapy
Verified
Journal Article
Open access
PDF file
HCHongli Chen
Hongli Chen
NLNa Li
Na Li
NLNa Liu
Na Liu
HZHongyu Zhu
Hongyu Zhu
CMChunyan Ma
Chunyan Ma
HYHuijuan Yin
Huijuan Yin
Alzheimer’s disease (AD) is a neurodegenerative disease. Amyloid β-protein (Aβ) is one of the key pathological features of AD, which is cytotoxic and can damage neurons, thereby causing cognitive dysfunction. Photobiomodulation (PBM) is a non-invasive physical therapy that induces changes in the intrinsic mechanisms of cells and tissues through low-power light exposure. Although PBM has been employed in the treatment of AD, the effect and precise mechanism of PBM on AD-induced neurological damage are still unclear. In vivo experiments, PBM (808 nm, 20 mW/cm2) was used to continuously interfere with APP/PS1 mice for 6 weeks, and then their cognitive function and AD pathological changes were evaluated. In vitro experiments, lipopolysaccharide (LPS) was used to induce microglia to model inflammation, and the effect of PBM treatment on microglia polarization status and phagocytic Aβ ability was evaluated. Hexokinase 2 (HK2) inhibitor 3-bromopyruvate (3BP) was used to study the effect of PBM treatment on mitochondrial energy metabolism in microglia. PBM further ameliorates AD-induced cognitive impairment by alleviating neuroinflammation and neuronal apoptosis, thereby attenuating nerve damage. In addition, PBM can also reduce neuroinflammation by promoting microglial anti-inflammatory phenotypic polarization; Promotes Aβ clearance by enhancing the ability of microglia to engulf Aβ. Among them, PBM regulates microglial polarization and inhibits neuronal apoptosis, which may be related to its regulation of mitochondrial energy metabolism, promotion of oxidative phosphorylation, and inhibition of glycolysis. PBM regulates neuroinflammatory response and inhibits neuronal apoptosis, thereby repairing Aβ-induced neuronal damage and cognitive dysfunction. Mitochondrial energy metabolism plays an important role in PBM in improving nerve injury in AD mice. This study provides theoretical support for the subsequent application of PBM in the treatment of AD.

24 June 2020 in Journal of Cellular Physiology
Verified
Journal Article
Closed access
PDF file
HCHongli Chen
Hongli Chen
YWYunhao Wang
Yunhao Wang
WTWen-Jun Tu
Wen-Jun Tu
HWHong Wang
Hong Wang
HYHuijuan Yin
Huijuan Yin
YLYingxin Li
Yingxin Li

22 October 2024 in Neural Regeneration Research
Verified
Journal Article
Open access
HCHongli Chen
Hongli Chen
NLNa Li
Na Li
YCYuanhao Cai
Yuanhao Cai
CMChunyan Ma
Chunyan Ma
YYYutong Ye
Yutong Ye
XWXunbin Wei
Xunbin Wei
In recent years, exosomes have garnered extensive attention as therapeutic agents and early diagnostic markers in neurodegenerative disease research. Exosomes are small and can effectively cross the blood–brain barrier, allowing them to target deep brain lesions. Recent studies have demonstrated that exosomes derived from different cell types may exert therapeutic effects by regulating the expression of various inflammatory cytokines, mRNAs, and disease-related proteins, thereby halting the progression of neurodegenerative diseases and exhibiting beneficial effects. However, exosomes are composed of lipid bilayer membranes and lack the ability to recognize specific target cells. This limitation can lead to side effects and toxicity when they interact with non-specific cells. Growing evidence suggests that surface-modified exosomes have enhanced targeting capabilities and can be used as targeted drug-delivery vehicles that show promising results in the treatment of neurodegenerative diseases. In this review, we provide an up-to-date overview of existing research aimed at devising approaches to modify exosomes and elucidating their therapeutic potential in neurodegenerative diseases. Our findings indicate that exosomes can efficiently cross the blood–brain barrier to facilitate drug delivery and can also serve as early diagnostic markers for neurodegenerative diseases. We introduce the strategies being used to enhance exosome targeting, including genetic engineering, chemical modifications (both covalent, such as click chemistry and metabolic engineering, and non-covalent, such as polyvalent electrostatic and hydrophobic interactions, ligand-receptor binding, aptamer-based modifications, and the incorporation of CP05-anchored peptides), and nanomaterial modifications. Research into these strategies has confirmed that exosomes have significant therapeutic potential for neurodegenerative diseases. However, several challenges remain in the clinical application of exosomes. Improvements are needed in preparation, characterization, and optimization methods, as well as in reducing the adverse reactions associated with their use. Additionally, the range of applications and the safety of exosomes require further research and evaluation.

23 June 2025 in Alzheimer's Research & Therapy
Verified
Journal Article
Open access
PDF file
CMChunyan Ma
Chunyan Ma
YYYutong Ye
Yutong Ye
XSXinyu Shi
Xinyu Shi
NLNa Li
Na Li
ZMZhiming Mu
Zhiming Mu
HCHongli Chen
Hongli Chen
Photobiomodulation (PBM), which utilizes specific light wavelengths to regulate cellular metabolism, signal transduction, and gene expression, has emerged as a promising intervention for enhancing cognitive function in Alzheimer’s disease (AD). The blood–brain barrier (BBB) plays a critical role in protecting the central nervous system, and its dysfunction is a major contributor to AD pathogenesis. Although PBM has shown therapeutic potential, its effects on BBB integrity and the underlying mechanisms remain unclear. Six-month-old female APP/PS1 transgenic mice were subjected to PBM intervention (808 nm, 20 mW/cm2) for six weeks. Cognitive function was assessed using behavioral tests, while biochemical and histological analyses were conducted to evaluate BBB integrity, β-amyloid (Aβ) deposition, and protein expression related to tight junction proteins (TJs). In vitro, an inflammatory model was established by treating brain microvascular endothelial cells (bEnd.3) with lipopolysaccharide (LPS) to induce an inflammatory response, and the mechanisms of PBM were further explored by analyzing mitochondrial function. PBM significantly improved cognitive deficits and anxiety-like behaviors in AD mice. It enhanced BBB integrity by upregulating the TJs Occludin, Claudin-5, and ZO-1, while also facilitating Aβ clearance via the low-density lipoprotein receptor-related protein 1 (LRP1) pathway and microglial phagocytosis, thereby reducing Aβ accumulation in the brain. Mechanistically, PBM attenuated apoptosis and mitochondrial oxidative stress while promoting mitochondrial energy metabolism. Notably, PBM markedly increased phosphorylated AMPK (p-AMPK) levels in the brains of AD mice. In vitro, the protective effects of PBM on BBB integrity were substantially diminished upon AMPK inhibition, confirming that PBM exerts its neuroprotective effects through the activation of the AMPK pathway. This study demonstrates that PBM enhances BBB integrity and mitigates Aβ pathology in AD mice by activating the AMPK signaling pathway, underscoring its potential as a novel, non-invasive therapeutic strategy for AD.

9 July 2020 in Lasers in Medical Science
Verified
Journal Article
Closed access
PDF file
HCHongli Chen
Hongli Chen
MTMengru Tu
Mengru Tu
JSJia Shi
Jia Shi
YWYunhao Wang
Yunhao Wang
ZHZhenhao Hou
Zhenhao Hou
JWJinhai Wang
Jinhai Wang

1 April 2016 in AIP Advances
Verified
Journal Article
Open access
PDF file
HCHongli Chen
Hongli Chen
HWHong Wang
Hong Wang
YLYingxin Li
Yingxin Li
WLWeichao Liu
Weichao Liu
CWChao Wang
Chao Wang
ZCZhuying Chen
Zhuying Chen
Low-level laser irradiation (LLLI) can enhance stem cell (SC) activity by increasing migration and proliferation. This study investigated the effects of LLLI on proliferation, enzymatic activity, and growth factor production in human umbilical cord mesenchymal SCs (hUC-MSCs) as well as the underlying mechanisms. hUC-MSCs were assigned to a control group (non-irradiation group) and three LLLI treatment groups (635 nm group, 808 nm group, and 635/808 nm group). Laser power density and energy density of 20 mW/cm2 and 12 J/cm2, respectively, were used for each experiment. The proliferation rate was higher in the 635 nm as compared to the other groups. LLLI at 808 nm did not induce cell proliferation. ROS levels in cells exposed to 635, 808, and 635/808 nm radiation were increased by 52.81%, 26.89%, and 21.15%, respectively, relative to the control group. CAT, tGPx, and SOD activity was increased. LLLI at 808 nm increased the levels of IL-1, IL-6, and NFκB but not VEGF. LLLI improved hUC-MSCs function and increased antioxidant activity. Dual-wavelength LLLI had more potent effects on hUC-MSCs than single-wavelength treatment. LLLI has potential applications in the preconditioning of hUC-MSCs in vitro prior to transplantation, which could improve the regenerative capacity of cells.